| Autor: |
McCauley, Thomas, Kurz, Jeffrey, Merlino, Patricia, Lewis, Scott, Gilbert, Madaline, Epstein, David, Marsh, H. |
| Zdroj: |
Pharmaceutical Research; February 2006, Vol. 23 Issue: 2 p303-311, 9p |
| Abstrakt: |
The aim of the study is to determine the bioactivity and effects of PEGylation on the pharmacokinetics in rabbit aqueous humor and plasma of an aptamer directed against TGFβ2.Pharmacological activity of anti-TGFβ2 aptamer in rabbit ocular fluid was demonstrated using a mink lung epithelial cell proliferation assay. For pharmacokinetic analyses, concentrations of aptamers in plasma and aqueous humor were determined over time following bilateral subconjunctival administration to Dutch-belted rabbits using a hybridization-based pseudo-enzyme-linked immunosorbent assay (ELISA) assay.Anti-TGFβ2 aptamer (ARC81) binds to human TGFβ2 with a KDof approximately 5 nM and inhibits the activity of human TGFβ2 in vitroin a cell-based assay with an IC50of approximately 100 nM. ARC81 blocks endogenously derived TGFβ2 in rabbit aqueous humor in vitrowith an IC50of approximately 200 nM and an IC90of approximately 1 μM. In vivoin rabbit, ARC81 [no polyethylene glycol (PEG)] entered systemic circulation rapidly (tmax= 1 h in plasma) relative to aptamer conjugates ARC117 (20 kDa PEG) and ARC119 (40 kDa PEG), which showed prolonged residence in the subconjunctival space and aqueous compartment (tmax= 6 and 12 h, respectively, in plasma). Both 20- and 40-kDa aptamer conjugates reached maximal concentrations (Cmax) in aqueous humor of 23–30 nM and remained at or above 1 nM for as long as 12 h.Pharmacologically active levels of anti-TGFβ2 aptamers can be sustained in the ocular fluid and local tissue environment over a 12-h period after single administration. Daily subconjunctival administration of PEGylated anti-TGFβ2 aptamers should allow further pharmacological evaluation of these agents in a rabbit conjunctival scarring model. Perioperative administration, via subconjunctival injection, may prove to be an effective means to deliver therapeutic quantities of TGFβ2 aptamer conjugates in trabeculectomy procedures. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink